Outcomes and implementation considerations for optimizing dolutegravir-based antiretroviral therapy among PLHIV in northern Uganda

In 2018, the Uganda Ministry of Health (MOH) adopted World Health Organization’s (WHO’s) guidance to switch first-line antiretroviral therapy (ART) from non-nucleoside reverse transcriptase inhibitors (NNRTIs) tom dolutegravir (TLD/DTG). This study conducted by  USAID Regional Health Integration to Enhance Services-North, Lango (RHITES-N, Lango) project and implemented by John Snow, Inc. (JSI), assesses the outcomes and implementation considerations for TLD/DTG optimization to guide policymaking decisions. This abstract was shared at the AIDS 2022 Conference.